Efficacy of 24-week Administration of Tenofovir Disoproxil Fumarate in the Management of Naïve Chronic Hepatitis B
DOI:
https://doi.org/10.3889/oamjms.2020.5424Keywords:
Chronic hepatitis B, Efficacy, HBeAg, HBV DNA, Tenofovir disoproxil fumarateAbstract
BACKGROUND: Chronic hepatitis B (CHB) is becoming a common liver abnormality worldwide. Thus, a series of good management is needed to prevent the progression and complications of hepatitis B infection. Tenofovir disoproxil fumarate (TDF) is one of the drugs of choice that’s used for CHB management.
AIM: Limited studies were found regarding the efficacy of tenofovir in dealing with CHB. Hence, the aim of this study is to determine the efficacy of TDF administration for 24 weeks in subjects with naïve CHB in Medan, Indonesia.
METHODS: Retrospective study was conducted in Haji Adam Malik Hospital Medan, Indonesia, between January and December 2019. Subjects were CHB patients aged 18 years or older and were treated TDF for 24 weeks. Demographic, clinical, and CHB disease progression parameters (serum alanine aminotransferase [ALT], hepatitis B envelope antigen [HBeAg], and hepatitis B virus deoxyribonucleic acid [HBV DNA]) data were obtained.
RESULTS: One hundred and twenty subjects were obtained and divided into 2 groups: HBeAg positive and HBeAg negative. Mean age of subjects was 46.5 ± 10.36 years in HBeAg positive group and 48.6 ± 10.67 years HBeAg negative group, with predominant males’ subjects in both groups (58.3% vs. 61.7%, respectively). Serum ALT normalization and undetectable serum HBV DNA were observed in more than 70% and 65% of subjects in both groups, respectively (both p < 0.001). Serum HBeAg loss was achieved in 10.8% subjects (p < 0.001). No subject showed serum HbsAg loss.
CONCLUSION: Our results are consonant with current clinical guidelines and other evidence literature. For both HBeAg-positive and HBeAg-negative populations, TDF administration for 24 weeks has good efficacy in naïve CHB patients.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Ecin SM, Başaran NC, Aladağ M. Evaluation of the effectiveness of tenofovir in chronic hepatitis B patients. Acta Med. 2020;51(1):9-14. https://doi.org/10.32552/0.actamedica.423
Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, et al. Hepatitis B surface antigen loss with tenofovir disoproxil fumarate plus peginterferon alfa-2a: Week 120 analysis. Dig Dis Sci. 2018;63(12):3487-97. https://doi.org/10.1007/ s10620-018-5251-9 PMid:30136045
Riset Kesehatan Dasar; 2018. Available from: https:// www.kemkes.go.id/resources/download/info-terkini/hasil-riskesdas-2018.pdf. [Last accessed on 2020 Oct 09].
Infodatin: Situasi Penyakit Hepatitis B di Indonesia Tahun; 2017. Available from: https://www.kemkes.go.id/resources/download/ pusdatin/infodatin/Infodatin-situasi-penyakit-hepatitis-B-2018. pdf. [Last accessed on 2020 Oct 09].
Muljono DH. Epidemiology of hepatitis B and C in republic of Indonesia. Euroasian J Hepatogastroenterol. 2017;7(1):55-9. PMid:29201773
Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang T, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 2014;146(5):1240-8. https://doi.org/10.1053/j. gastro.2014.01.044 PMid:24462735
Lovett GC, Nguyen T, Iser DM, Holmes JA, Chen R, Demediuk B, et al. Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience. World J Hepatol. 2017;9(1):48-56. https://doi.org/10.4254/wjh.v9.i1.48 PMid:28105258
Kozielewicz D, Halota W, Wietlicka-Piszcz M. Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment. Hepatol Int. 2016;10(2):302-9. https://doi.org/10.1007/s12072-015-9681-6 PMid:26612013
Örmeci N, Özbaş B, Güner R, Özkan H, Yalçı A, Çoban Ş, et al. Tenofovir-best hope for treatment of chronic hepatitis B infection? Turk J Gastroenterol. 2015;26(4):322-7. https://doi.org/10.5152/tjg.2015.0164 PMid:26038999
Shi H, Huang M, Lin G, Li X, Wu Y, Jie Y, et al. Efficacy comparison of tenofovir and entecavir in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Biomed Res Int. 2016;2016:6725073. https://doi.org/10.1155/2016/6725073 PMid:27034945
Lok AS. Hepatitis B treatment: What we know now and what remains to be researched. Hepatol Commun. 2018;3(1):8-19. https://doi.org/10.1002/hep4.1281 PMid:30619990
Yu HM, Kwon SY, Kim J, Chung HA, Kwn SW, Jeong TG, et al. Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic hepatitis B patients. Saudi J Gastroenterol. 2015;21(3):146-51. https://doi.org/10.4103/1319-3767.157558 PMid:26021773
Liang X, Gao Z, Xie Q, Zhang J, Sheng J, Cheng J, et al. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Hepatol Int. 2019;13(3):260-9. https://doi.org/10.1007/ s12072-019-09943-6 PMid:30977033
Jiang T, Su B, Song T, Zhu Z, Xia W, Dai L, et al. Immunological efficacy of tenofovir disproxil fumarate-containing regimens in patients with HIV-HBV coinfection: A systematic review and meta-analysis. Front Pharmacol. 2019;10:1023. https://doi.org/10.3389/fphar.2019.01023 PMid:31572195
Chen L, Wang X, Zhang Q, Gong J, Shen S, Yin W, et al. Efficacy of tenofovir-based combination therapy versus tenofovir monotherapy in chronic hepatitis B patients presenting with suboptimal responses to pretreatment: A meta-analysis. Gastroenterol Res Pract. 2016;2016:7214020. https://doi.org/10.1155/2016/7214020 PMid:26880896
Gani RA. Perbandingan profil keamanan tenofovir dan telbivudin terhadap fungsi ginjal pada pasien hepatitis B di Indonesia. J Penyakit Dalam Indone. 2018;5(3):129-34. https://doi.org/10.7454/jpdi.v5i3.213
Song JE, Lee CH, Kim BS. Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice. Korean J Intern Med. 2019;34(4):802-10. https://doi.org/10.3904/kjim.2019.037 PMid:30959583
Zheng S, Liu L, Lu J, Zhang X, Shen H, Zhang H, et al. Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection: A 2-year prospective study. Medicine (Baltimore). 2019;98(42):e17590. https://doi.org/10.1097/md.0000000000017590 PMid:31626130
Wu IT, Hu TH, Hung CH, Lu SN, Wang JH, Lee CM, et al. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naïve chronic hepatitis B patients with high viraemia: A retrospective cohort study. Clin Microbiol Infect. 2017;23(7):464-9. https://doi.org/10.1016/j.cmi.2017.02.001 PMid:28189857
Xing T, Xu H, Cao L, Ye M. HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term nucleos(t)ide analog treatment: A systematic review and network meta-analysis. PLoS One. 2017;12(1):e0169444. https://doi.org/10.1371/journal.pone.0169444 PMid:28107377
Pereira CV, Tovo CV, Grossmann TK, Mirenda H, Dal-Pupo BB, De Almeida PR, et al. Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in Southern Brazil. Mem Inst Oswaldo Cruz. 2016;111(4):252-7. https://doi.org/10.1590/0074-02760150390
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Darmadi Darmadi, Gontar Alamsyah Siregar (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
